Relationship of C-Reactive Protein to Adverse Cardiovascular Events in Patients Treated by Percutaneous Coronary Intervention for Stable Angina Pectoris
Abstrakt
Low-grade inflammation as detected by increased C-reactive protein (CRP) levels predicts the risk of cardiovascular events. However, there is still controversy over the mid-term predictive value of CRP in patients referred for elective percutaneous coronary revascularization (PCI) for stable angina pectoris.
The aim of this study was to assess the relationship between baseline CRP level and mid-term outcome of patients undergoing PCI. Two groups of patients with stable angina pectoris were prospectively studied.
Group A consisted of 150 consecutive patients with a CRP level 3 mg/L undergoing PCI at our institution. Comparing both groups of patients. the analysis confirmed a significant difference between medians of the CRP levels (0.5 versus 8 mg/ml; P 1.5 ng/mL reached 12% in group A and 14% in group B (P = 0.73).
Analyses were repeated with adjustment for significant baseline variables, which did not change our findings. The incidence of adverse cardiovascular events during six month follow-up was 13% in both groups (NS).
Increased CRP serum prior to PCI was not associated with the risk and extent of procedure-related myocardial injury measured by Trif release and does not portend heightened cardiovascular risk at six months after percutaneuos revascularization. On the other hand, a CRP level > 3 mg/L was associated with a higher occurence of cardiovascular risk factors (smoking, hypertension, hypertriglyceridemia, and diabetes mellitus).